These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30836001)

  • 1. Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Verma K; Zang T; Penning TM; Trippier PC
    J Med Chem; 2019 Apr; 62(7):3590-3616. PubMed ID: 30836001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.
    Morell A; Novotná E; Milan J; Danielisová P; Büküm N; Wsól V
    Arch Toxicol; 2021 Jan; 95(1):67-78. PubMed ID: 33025066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
    Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
    Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.
    Penning TM
    Expert Opin Ther Pat; 2017 Dec; 27(12):1329-1340. PubMed ID: 28895472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
    Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
    Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
    Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
    Arch Toxicol; 2018 Sep; 92(9):2845-2857. PubMed ID: 29992508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines.
    Verma K; Zang T; Gupta N; Penning TM; Trippier PC
    ACS Med Chem Lett; 2016 Aug; 7(8):774-9. PubMed ID: 27563402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
    Byrns MC; Steckelbroeck S; Penning TM
    Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
    Penning TM
    Mol Cell Endocrinol; 2019 Jun; 489():82-91. PubMed ID: 30012349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold.
    Pippione AC; Kilic-Kurt Z; Kovachka S; Sainas S; Rolando B; Denasio E; Pors K; Adinolfi S; Zonari D; Bagnati R; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
    Eur J Med Chem; 2022 Jul; 237():114366. PubMed ID: 35447434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico study of novel alpha tocopheroids as effective inhibitors of aldo-keto reductase 1c3 (AKR1C3) enzyme.
    Basu T; Upadhyay AK
    J Biomol Struct Dyn; 2024 Sep; 42(15):7715-7729. PubMed ID: 37534497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
    Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
    Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis and Cytotoxicity Evaluation of Novel Indole Derivatives Containing Benzoic Acid Group as Potential AKR1C3 Inhibitors.
    Sun M; Zhou Y; Zhuo X; Wang S; Jiang S; Peng Z; Kang K; Zheng X; Sun M
    Chem Biodivers; 2020 Dec; 17(12):e2000519. PubMed ID: 33111427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
    Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
    Biochem Pharmacol; 2018 Oct; 156():22-31. PubMed ID: 30077642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
    Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.
    Morell A; Budagaga Y; Vagiannis D; Zhang Y; Laštovičková L; Novotná E; Haddad A; Haddad M; Portillo R; Hofman J; Wsól V
    Arch Toxicol; 2022 Dec; 96(12):3265-3277. PubMed ID: 35972551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer.
    Liu Y; Chen Y; Jiang J; Chu X; Guo Q; Zhao L; Feng F; Liu W; Zhang X; He S; Yang P; Fang P; Sun H
    Eur J Med Chem; 2023 Feb; 247():115013. PubMed ID: 36566714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
    Bukum N; Novotna E; Morell A; Hofman J; Wsol V
    Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.